Morsa Images
Becton, Dickinson and Company (NYSE:BDX) is up 8% since early December. The price per share sits around $238 and is not too far off from its 2024 peak in March at $247 per share. It’s no question that BDX and the healthcare
Becton, Dickinson: Hold, Momentum Is Gaining, Just Need More Growth
Summary
- Becton, Dickinson and Company is rated a hold due to low growth, valuation concerns, and underperformance compared to healthcare equipment peers.
- BDX's acquisition of Edwards Lifesciences’ Critical Care product group and rising free cash flow are positive indicators for future growth.
- The stock's momentum is improving, but geopolitical risks and global headwinds warrant caution for potential investors.
- Despite a moderate dividend yield and 52 years of dividend growth, BDX's valuation and growth prospects make it a risky buy currently.
I am an investment author with passion for finance and global markets. I enjoy gearing toward economic analysis, specifically on a macro level. Through current and forward looking market trends, fundamental and technical analysis, my goal is to provide investors and readers with the tools and knowledge to make informed and confident investment decisions. I am always open to feedback and hope you enjoy my writing!
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.